Experimental combo for tough prostate cancer shows early promise but trial halted
NCT ID NCT00183937
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, bortezomib and docetaxel, in 15 men with advanced prostate cancer that had stopped responding to hormone therapy. The goal was to see if the combo could lower PSA levels and ease pain. The trial was terminated early, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bortezomib and docetaxel
- What this could lead to
- If it works, this could point toward a new combination therapy for advanced prostate cancer that has stopped responding to hormone treatment.
- What could go wrong
- This trial was terminated early with only 15 participants, so results are very limited. The combination may cause serious side effects and may not improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?